Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study

AIMS: To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin with dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk associations with major adverse cardiovascular (CV) events (MACE; non‐fatal myocardial infarction, non‐fatal stroke or cardiovascular mortality), ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Persson, Frederik, Nyström, Thomas, Jørgensen, Marit E., Carstensen, Bendix, Gulseth, Hanne L., Thuresson, Marcus, Fenici, Peter, Nathanson, David, Eriksson, Jan W., Norhammar, Anna, Bodegard, Johan, Birkeland, Kåre I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811811/
https://www.ncbi.nlm.nih.gov/pubmed/28771923
http://dx.doi.org/10.1111/dom.13077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811811/
https://www.ncbi.nlm.nih.gov/pubmed/28771923
http://dx.doi.org/10.1111/dom.13077

Ejemplares similares